Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 2495

    1.

    Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.

    Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T.

    Breast Cancer Res. 2008;10(6):R101. Epub 2008 Dec 3.

    PMID:
    19055754
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.

    DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M.

    Ann Oncol. 2004 Oct;15(10):1510-6.

    PMID:
    15367412
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.

    Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y, Maehara Y.

    Breast Cancer Res Treat. 2007 Mar;101(3):249-57. Epub 2006 Sep 28.

    PMID:
    17006756
    [PubMed - indexed for MEDLINE]
    5.

    Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.

    Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.

    Endocr Relat Cancer. 2005 Dec;12(4):983-98.

    PMID:
    16322337
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

    Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR.

    Clin Cancer Res. 2009 Jul 15;15(14):4649-64. Epub 2009 Jun 30.

    PMID:
    19567590
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

    McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

    Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

    PMID:
    16854453
    [PubMed - indexed for MEDLINE]
    9.

    Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

    Xu G, Zhang W, Bertram P, Zheng XF, McLeod H.

    Int J Oncol. 2004 Apr;24(4):893-900.

    PMID:
    15010827
    [PubMed - indexed for MEDLINE]
    10.

    Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.

    Hartmann W, Digon-Söntgerath B, Koch A, Waha A, Endl E, Dani I, Denkhaus D, Goodyer CG, Sörensen N, Wiestler OD, Pietsch T.

    Clin Cancer Res. 2006 May 15;12(10):3019-27.

    PMID:
    16707597
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.

    Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefström J, Hautaniemi S, Monni O.

    BMC Genomics. 2008 Jul 24;9:348.

    PMID:
    18652687
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.

    López-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL.

    Int J Cancer. 2010 Mar 1;126(5):1121-31.

    PMID:
    19685490
    [PubMed - indexed for MEDLINE]
    13.

    Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.

    Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV.

    Mol Endocrinol. 2003 Apr;17(4):575-88. Epub 2003 Jan 2. Erratum in: Mol Endocrinol. 2003 Sep;17(9):1892.

    PMID:
    12554765
    [PubMed - indexed for MEDLINE]
    Free Article
    14.

    Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.

    Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N.

    Cancer Res. 2005 Dec 1;65(23):11018-25.

    PMID:
    16322251
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Activation of PI3K is associated with reduced survival in renal cell carcinoma.

    Merseburger AS, Hennenlotter J, Kuehs U, Simon P, Kruck S, Koch E, Stenzl A, Kuczyk MA.

    Urol Int. 2008;80(4):372-7. Epub 2008 Jun 27.

    PMID:
    18587247
    [PubMed - indexed for MEDLINE]
    16.

    PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.

    Bouali S, Chrétien AS, Ramacci C, Rouyer M, Becuwe P, Merlin JL.

    Oncol Rep. 2009 Mar;21(3):731-5.

    PMID:
    19212633
    [PubMed - indexed for MEDLINE]
    17.

    Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?

    Hlobilkova A, Ehrmann J, Sedlakova E, Krejci V, Knizetova P, Fiuraskova M, Kala M, Kalita O, Kolar Z.

    Neoplasma. 2007;54(4):334-41.

    PMID:
    17822324
    [PubMed - indexed for MEDLINE]
    18.

    Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.

    Sengupta S, Schiff R, Katzenellenbogen BS.

    Breast Cancer Res Treat. 2009 Sep;117(2):243-51. Epub 2008 Sep 19.

    PMID:
    18807177
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    19.

    PTEN sensitizes epidermal growth factor-mediated proliferation in endometrial carcinoma cells.

    Tang LL, Yokoyama Y, Wan X, Iwagaki S, Niwa K, Tamaya T.

    Oncol Rep. 2006 Apr;15(4):855-9.

    PMID:
    16525671
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk